Resource Centre

Nand Singh, Medical Director contributions to Bial Study Paper. This paper documents the study - absorption, metabolism and excretion of opicapone (2,5-dichloro-3-(5-[3,4-dihydroxy-5-nitrophenyl]-1,2,4-oxadiazol-3-yl)-4,6-dimethylpyridine 1-oxide), a selective catechol-O-methyltransferase inhibitor investigations.

Chris Roe, Quotient Sciences' Principal Research Fellow, discusses strategies for overcoming biopharmaceutic challenges for small molecules in today’s drug development.

A Quotient Sciences Poster by Erika Reategui, Director, GCP Quality Assurance, Quality Assurance: Why Archiving is a Crucial Part of Any Clinical Trial

Quotient Sciences and Kadmon co-authored scientific publications for their recent NDA approved drug Belumosudil.

Quotient Sciences and Kadmon co-authored scientific publications on their recent NDA approved drug Belumosudil.

Quotient Sciences and Kadmon co-authored scientific publications on their recent NDA approved drug Belumosudil.

Quotient Sciences, Kadmon and Nuventra, Co-Authored Scientific Publication assessing Belumosudil, a selective Rho-associated protein kinase 2 inhibitor. Inhibition of Rho-associated protein kinase 2 has emerged as a promising treatment for chronic graft-versus-host disease by restoring immune homeostasis and reducing fibrosis.

Quotient Sciences and Astrazeneca Co-Authored Scientific Publication evaluating the use of intravenous 14C dosing in healthy volunteer subjects to understand the metabolism for an inhaled drug product.

Quotient Sciences Scientific Publication- Development of a Once‑Daily Modified‑Release Formulation for the Short Half‑Life RIPK1 Inhibitor GSK2982772 using DiffCORE Technology

Effect of Miricorilant, a Selective Glucocorticoid Receptor Modulator, on Olanzapine-Associated Weight Gain in Healthy Subjects.

Quotient Sciences Poster : An Integrated Radiolabelled Study to Determine the Mass Balance, Metabolite Profile and Identification and Absolute Bioavailability of Nolasiban in Healthy Female Subjects